Search

Your search keyword '"Vallisa, Daniele"' showing total 6 results
Start Over Author "Vallisa, Daniele" Journal leukemia & lymphoma
6 results on '"Vallisa, Daniele"'

1. Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi

Author

Arcari, Annalisa, primary, Morello, Lucia, additional, Vallisa, Daniele, additional, Marcheselli, Luigi, additional, Tecchio, Cristina, additional, Quaglia, Francesca Maria, additional, Tisi, Maria Chiara, additional, Zilioli, Vittorio Ruggero, additional, Di Rocco, Alice, additional, Perrone, Tommasina, additional, Gini, Guido, additional, Dogliotti, Irene, additional, Bianchetti, Nicola, additional, Bozzoli, Valentina, additional, De Philippis, Chiara, additional, Alvarez De Celis, Maria Isabel, additional, Chiappella, Annalisa, additional, Fabbri, Alberto, additional, Pelosini, Matteo, additional, Merli, Michele, additional, Molinari, Anna Lia, additional, Sciarra, Roberta, additional, Volpetti, Stefano, additional, Hohaus, Stefan, additional, Nassi, Luca, additional, and Visco, Carlo, additional

Published
2021
Full Text
View/download PDF

2. Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide

Author

Maffei, Rossana, primary, Fiorcari, Stefania, additional, Martinelli, Silvia, additional, Benatti, Stefania, additional, Bulgarelli, Jenny, additional, Rizzotto, Lara, additional, Debbia, Giulia, additional, Santachiara, Rita, additional, Rigolin, Gian Matteo, additional, Forconi, Francesco, additional, Rossi, Davide, additional, Laurenti, Luca, additional, Palumbo, Giuseppe A., additional, Vallisa, Daniele, additional, Cuneo, Antonio, additional, Gaidano, Gianluca, additional, Luppi, Mario, additional, and Marasca, Roberto, additional

Published
2017
Full Text
View/download PDF

3. Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study

Author

Arcari, Annalisa, primary, Chiappella, Annalisa, additional, Spina, Michele, additional, Zanlari, Luca, additional, Bernuzzi, Patrizia, additional, Valenti, Vanessa, additional, Tani, Monica, additional, Marasca, Roberto, additional, Cabras, Maria Giuseppina, additional, Zambello, Renato, additional, Santagostino, Alberto, additional, Ilariucci, Fiorella, additional, Carli, Giuseppe, additional, Musto, Pellegrino, additional, Savini, Paolo, additional, Marino, Dario, additional, Ghio, Francesco, additional, Gentile, Massimo, additional, Cox, Maria Christina, additional, and Vallisa, Daniele, additional

Published
2015
Full Text
View/download PDF

4. Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.

Author

Maffei, Rossana, Fiorcari, Stefania, Martinelli, Silvia, Benatti, Stefania, Bulgarelli, Jenny, Rizzotto, Lara, Debbia, Giulia, Santachiara, Rita, Rigolin, Gian Matteo, Forconi, Francesco, Rossi, Davide, Laurenti, Luca, Palumbo, Giuseppe A., Vallisa, Daniele, Cuneo, Antonio, Gaidano, Gianluca, Luppi, Mario, and Marasca, Roberto

Subjects
CHRONIC lymphocytic leukemia, CLINICAL trials, CYTOKINES, GENE expression, CANCER patients
Abstract

Lenalidomide is a therapeutically effective drug in chronic lymphocytic leukemia (CLL). Twenty-seven CLL patients were treated with lenalidomide in a phase II clinical trial. Ten patients were grouped as responders (R) and 6 as nonresponders (NR). We evaluated T lymphocytes, NK, monocytes and dendritic cells at baseline and after treatment. A gene expression analysis was performed on 16 CLL samples collected before treatment. The levels of immune cells or immune-related cytokines are not different between R and NR patients. However, CLL patients sensitive to lenalidomide clearly show a peculiar gene expression profile in leukemic cells. The most up-regulated gene (fold change =  +23 in R vs. NR) is Wnt inhibitor SHISA homolog 3 (SHISA3). SHISA3highCLL are characterized by a restrained activation of Wnt signaling and sensibility to lenalidomide-induced apoptosis. In conclusion, SHISA3 is a candidate gene for the identification of CLL patients who will benefit of lenalidomide treatment as single agent. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

5. Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study.

Author

Arcari, Annalisa, Chiappella, Annalisa, Spina, Michele, Zanlari, Luca, Bernuzzi, Patrizia, Valenti, Vanessa, Tani, Monica, Marasca, Roberto, Cabras, Maria Giuseppina, Zambello, Renato, Santagostino, Alberto, Ilariucci, Fiorella, Carli, Giuseppe, Musto, Pellegrino, Savini, Paolo, Marino, Dario, Ghio, Francesco, Gentile, Massimo, Cox, Maria Christina, and Vallisa, Daniele

Subjects
LYMPHOMA treatment, RITUXIMAB, MONOCLONAL antibodies, INFLIXIMAB, STEM cell transplantation
Abstract

Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not suitable for high dose chemotherapy with autologous stem cell transplantation (ASCT) has a dismal prognosis and no standard therapy. We designed an Italian multicenter retrospective study aimed at evaluating the safety and efficacy of rituximab plus bendamustine (R–B) as salvage treatment in patients not eligible for ASCT because of age and/or comorbidity or in patients with post-ASCT recurrence. Fifty-five patients with a median age of 76 years were included. The overall response rate was 50%, including 28% complete remission and 22% partial remission. The median overall survival (OS) was 10.8 months. The median progression free survival (PFS) was 8.8 months. Eleven patients are still alive and in complete remission at last follow-up (12–71 months). Toxicity was moderate, mainly grades 1 and 2. R–B showed promising efficacy results with an acceptable toxicity profile and should be further investigated, possibly in combination with novel drugs. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

6. ProMECE-CytaBOM vs MACOP-B in Advanced Aggressive Non-Hodgkin's Lymphoma: Long Term Results of a Multicenter Study of the Italian Lymphoma Study Group (GISL)

Author

Silingardi, Vittorio, primary, Federico, Massimo, additional, Cavanna, Luigi, additional, Avanzini, Paolo, additional, Gobbi, Paolo G., additional, Lombardo, Marco, additional, Carotenuto, Mario, additional, Frassoldati, Antonio, additional, Pieresca, Carla, additional, Vallisa, Daniele, additional, Merli, Francesco, additional, Ascari, Edoardo, additional, and Mauri, Carlo, additional

Published
1995
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results